Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Volume is 90,000,000 > NUWE
Porshe needs to be on big boards. This will attract many tutes. This equity will attract many new investors. Pension plans, Tech university endowment funds, and mutual funds will scoop up Porshe shares.
Awesome medical technology > Several PT's of 2.50+ by analysts over last few months. NUWE should settle between $2.50 and $5.55+ in September.
Massive volume w/ 10M float. NUWE
Trading float is miniscule! 10M shares.
MOMO/ FOMO / HERD > 52 WEEK HI > THIS WEEK !!!!!
NUWE is a great $$$$$ opportunity.
Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients
7:00 am ET August 31, 2022 (Globe Newswire) Print
EQNX::TICKER_START (NASDAQ:NUWE), EQNX::TICKER_END Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the publication of key clinical data supporting the use of ultrafiltration with the Aquadex FlexFlow(R) System in high-risk postoperative coronary artery bypass grafting (CABG) patients in the Journal of Cardiac Surgery.
The study, "The Use of Simple Ultrafiltration Technology as a Fluid Management Strategy for High-Risk Coronary Artery Bypass Grafting Surgery," is a real-world retrospective review of postoperative isolated CABG patients who were treated in the Division of Cardiothoracic Surgery at Baylor Scott & White Health in Temple, Texas between January 1, 2020 and July 31, 2021. A total of 254 CABG procedures were performed during this period, and ultrafiltration was used in 17 (6.7%) patients. Despite an elevated mean Society of Thoracic Surgeons mortality score of 5.7% (range 0.6-50.0), the 30-day survival rate of patients treated with ultrafiltration was 100%.
"Ultrafiltration technology has been used for decades to successfully treat advanced heart failure patients and data hav been published to demonstrate its outcomes, but its application in cardiac surgery to treat fluid overload is innovative," said Daniel Beckles, M.D., Surgical Director of Heart Transplantation and Mechanical Circulatory Support at Baylor Scott & White Health and the study's lead author. "These favorable results are consistent with the clinical findings in other large academic centers using ultrafiltration technology in cardiac surgery, and we are eager to gather additional multi-institutional data about the use of Aquadex for this challenging patient population."
According to the Society of Thoracic Surgery Adult Cardiac Surgery Database, isolated CABG for coronary artery disease (CAD) is the most commonly performed cardiac surgery procedure, with over 162,000 per year. The increased age of patients, in addition to risk factors for CAD (hypertension, diabetes, obesity and chronic kidney disease), increases the perioperative risk for acute kidney injury and subsequent fluid overload. Excess fluid overload in the perioperative phase of care has been associated with increased morbidity and mortality for CABG patients.
"We are pleased with the results of this first-of-its-kind study highlighting the benefits of Aquadex therapy for high-risk CABG patients," said Nestor Jaramillo, Jr., President and CEO of Nuwellis. "The Aquadex System offers a significant opportunity to the medical community to improve clinical outcomes. In 2019, we made the decision to expand our strategic focus to include the use of Aquadex in critical care (cardiac surgery) and pediatric settings. Today, critical care represents approximately 40% of our total revenue, confirming the execution of the strategy and the clinical value of the Aquadex System in this patient segment."
In addition to cardiovascular surgery, Nuwellis continues to make significant progress in other key areas of patient need, including heart failure and pediatrics. The company recently announced the first patient enrolled in its REVERSE-HF clinical study, which is evaluating the clinical outcomes and economic value of its Aquadex(R) ultrafiltration therapy in comparison to intravenous (IV) diuretics for the treatment of fluid overload in patients with worsening heart failure. Nuwellis is also developing a new, fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. This device is being funded in part by a $1.7 million grant from the National Institutes of Health (NIH). Nuwellis has partnered with Minneapolis-based research and development firm Koronis Biomedical Technologies Corporation (KBT), the grant recipient, to design and develop a custom pediatric product that will enable clinicians to better care for babies with limited kidney function.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow(R) system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minn., with a wholly-owned subsidiary in Ireland.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and predictable method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2022 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Bowdish ME, D'Agostino RS, Thourani VH, Schwann TA, Krohn C, Desai N, Shahian DM, Fernandez FG, Badhwar V. STS Adult Cardiac Surgery Database: 2021 Update on Outcomes, Quality, and Research. Ann Thorac Surg 2021;111:1770-80.
Pal S. Primary Causes of End-Stage Renal Disease. US Pharm. 2016;41(8):6.
CONTACTS
INVESTORS:
George Montague, CFA
Chief Financial Officer, Nuwellis, Inc.
ir@nuwellis.com
Leigh Salvo
Gilmartin Group LLC
leigh@gilmartinir.com
MEDIA:
Sarah Lundberg
Health+Commerce
sarahlundberg@healthandcommerce.com
https://ml.globenewswire.com/media/f9aa7d0f-d4fa-4740-a3dd-a3aca02090b6/small/picture1-jpg.jpg
CONTACTS
INVESTORS:
George Montague, CFA
Chief Financial Officer, Nuwellis, Inc.
ir@nuwellis.com
Leigh Salvo
Gilmartin Group LLC
leigh@gilmartinir.com
MEDIA:
Sarah Lundberg
Health+Commerce
sarahlundberg@healthandcommerce.com
https://ml.globenewswire.com/media/f9aa7d0f-d4fa-4740-a3dd-a3aca02090b6/small/picture1-jpg.jpg
comtex tracking
NYC banks closing ATM enclosures at night. Too many homeless using the enclosures as toilets.
An illegal migrant waving a tennis racket as he crosses southern border would make a great photograph. Give it to Peter Doucey. He could show it @ next White House press briefing!
SEC filing 8-k > On August 30, 2022, Oncternal Therapeutics, Inc. submitted an Investigational New Drug Application (“IND”) for ONCT-808, its autologous chimeric antigen receptor T cell (CAR-T) targeting Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). The IND must be accepted by the U.S. Food and Drug Administration prior to commencing a clinical study of ONCT-808.
Porsche 911 > "All my friends drive Porsches, I must make amends...oh Lord, don't ya buy me a Mercedes Benz.."
Janice Joplin
POAHY
$olid day! > Porsche's initial public offering is getting close. It's going to be big deal.
LET'S GO PORSHE !!!!!
POAHY
7.30
POAHY
7.24 x 7.26 > Pacing upwards towards opening bell.
Nidec's annual sales were 1.9 trillion Japanese yen in March 2022, and the company is aiming for 4 trillion Japanese yen by March 2026. Under its Corporate Slogan, "All for Dreams", Nidec is challenging to expand the promising ESS market strategically to contribute to the realization of a carbon-neutral society. To learn more about Nidec, please visit www.nidec.com/en/
The Company's Kandy platform sweetened the pot. The sale of the entire business or selected assets are on the table.
Good link! Folks need to be aware of their surroundings.
Self-Defense Exercise: Think Like a Criminal
https://www.nrawomen.com/content/self-defense-exercise-think-like-a-criminal/
LET'S GO AHI !
OK Bluto ! Get back to your Animal House!
POAHY
AHI ratcheting up into closing bell.
Let's go OLB !
Let's go OLB !
Just bought a few. She'll run well into the 2's tomorrow!
SEPTEMBER > PORSHE > IPO > GOING TO BE HUGE!
Sports car brands can achieve higher valuations than traditional auto makers. Ferrari (RACE) stock, for instance, trades for about 35 times estimated 2023 earnings. Volkswagen stock trades for about five times.
Porsche SE Could Become a More Attractive Investment -- Market Talk
2:08 am ET August 19, 2022 (Dow Jones) Print
0607 GMT - Volkswagen's biggest shareholder, Porsche SE, so far is a passive holding company with high litigation claims and not an attractive investment, though the company might be changing into an actively managed holding amid the potential stock-market listing of the German auto maker's sports-car brand Porsche AG, analysts at Jefferies say in a research note. While Porsche SE has so far made only very limited efforts to diversify its assets, it looks set to acquire a stake in Porsche AG in the case of an IPO, the analysts say. "This would be positive, opening the possibility that Porsche SE could become an actively managed vehicle to grow and diversify family wealth like Exor has been for the Agnelli family," they say. (kim.richters@wsj.com)
(END) Dow Jones Newswires
August 19, 2022 02:08 ET (06:08 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Porsche's initial public offering is getting close. It's going to be big.
POAHY
Porsche Could Be Worth as Much as All of Volkswagen in an IPO -- Barrons.com
8:15 am ET August 26, 2022 (Dow Jones) Print
Al Root
Porsche's initial public offering is getting close. It's going to be big.
Friday, Bloomberg reported that Porsche has lined up investor interest for a deal. Building out a book of investors who will buy shares is part of the process in any stock offering.
Volkswagen (ticker: VOW3. Germany), which controls the Porsche brand, didn't immediately respond to a request for comment.
Porsche Automobil Holding SE (PAH3. Germany) is a listed company that holds 53.3% of the ordinary stock in Volkswagen. It is a long-term investor in Volkswagen.
Porsche AG, meanwhile, is the entity that makes, well, Porsches. Porsche AG will be the company raising money by selling shares. Volkswagen will likely retain a stake in the maker of iconic sports cars.
The IPO is one potential way to unlock some of the value of one of Volkswagen's brands for Volkswagen investors. Along with Porsche, Volkswagen makes Lamborghinis, Bugattis, and Bentleys, among other vehicles.
Sports car brands can achieve higher valuations than traditional auto makers. Ferrari (RACE) stock, for instance, trades for about 35 times estimated 2023 earnings. Volkswagen stock trades for about five times.
The IPO is slated for September, according to Bloomberg, and the valuation could hit $60 billion to $85 billion. For context, Volkswagen has a market capitalization of about $85 billion, so the upper end of the Porsche valuation range is the same as the entire valuation for VW these days.
With the car business, sometimes less is more. Ferrari has a market cap of roughly $37 billion. It delivered about 11,000 cars in 2021, for a valuation of roughly $3.3 million a car. Porsche delivered about 300,000 cars that same year. At $85 billion, Porsche stock would be valued at about $280,000 a car. VW delivered more than 7.7 million. It is valued at about $11,000 a car sold.
VW stock was up about 1.3% in overseas trading early on Friday. It's a positive reaction, but it isn't huge because the market has expected the IPO for a while. Futures on the S&P 500 and Dow Jones Industrial Average were down 0.3% and 0.2%, respectively.
Write to Al Root at allen.root@dowjones.com
(END) Dow Jones Newswires
August 26, 2022 08:15 ET (12:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
The OLB Group Inc (NASDAQ: OLB) shares are trading higher Monday after the company announced it has entered into a collaboration for exclusive licensing and transaction sharing with Cuentas to upgrade its Bodega network and help the company evolve into financial centers.
Cuentas' collaboration with OLB enables the company to provide new POS systems in locations for users to load cash on their mobile app and digital wallet among other financial mobile apps associated with major U.S. brands.
The collaboration includes a revenue share for profits resulting from the sale or rental of OLB point-of-sale devices, as well as for the sale of digital e-gift content and gaming for domestic and international wireless services.
"We at OLB Group see the opportunity to expand our merchant services base in a market that we currently don't have a footprint and also provide existing products and services to those bodegas and convenient stores as additional stream for revenues besides the 10,500 merchants that we currently service", said Ronny Yakov, CEO of OLB Group.
The OLB Group is a fintech e-commerce merchant services provider and Bitcoin (CRYPTO: BTC) crypto mining enterprise.
See Also: Khiron Q2 Revenue Grows 60% YoY, Despite Decline In Medical Cannabis Sales In Germany
OLB Price Action: OLB has a 52-week high of $2.79 and a 52-week low of 83 cents.
The stock was up 24.6% at $2.11 at press time, according to Benzinga Pro.
Nice AHI ..... Hope you're makin bank!
HUGE > Estate Holdings, Inc. (“DREH”), a wholly owned subsidiary of DMINT, Inc., a wholly owned subsidiary of the Company (“DMINT”) which is a wholly owned subsidiary of The OLB Group, Inc. (the “Company”) entered into a Contract for Sale of Realty (the “Contract”) related to the purchase of property. DREH closed the purchase of 4.73 acres of land and a building located at 565 Industrial Park Drive, Selmer, McNairy County, Tennessee for a purchase price of $408,000.00. DMINT intends to convert the building into a cryptocurrency mining data center powered on the local power grid. The location is expected to have capacity for up to 9,000 cryptocurrency mining machines.
Billionaire Ron Baron Is 'Incredibly Bullish' On Tesla, SpaceX And This Apparel Company He Calls 'The Lululemon Of Healthcare'
4:28 pm ET August 25, 2022 (Benzinga) Print
There aren't many investors with a 20-year time horizon at the age of 79, but that's exactly how far billionaire investor Ron Baron is looking ahead, and it's safe to say he's optimistic about what's to come.
"I am incredibly bullish for my children, for my grandchildren and for me for the next 20 years," Baron said Thursday on CNBC's "Squawk Box."
Baron's Thesis: Baron told CNBC that from the year 0 to the year 1500, the size of the economy and the amount of people doubled. Following the Industrial Revolution around 1800, the economy went up by a factor of 100 over the next 200 years.
"Over the last 50 years, the growth is accelerating. And it's going to accelerate even further because now you have the digitization of everything taking place," Baron said.
What Baron Is Buying: The longtime Tesla Inc (NASDAQ: TSLA) bull's most recent purchases include an additional $100 million investment in Elon Musk's SpaceX and an investment in healthcare apparel company FIGS Inc (NYSE: FIGS).
"FIGS, you haven't heard very much about, but you will soon. It's the Lululemon of healthcare and we invested about $100 million there," Baron said.
FIGS, you haven't heard very much about, but you will soon. It's the Lululemon of healthcare and we invested about $100 million there," Ron Baron said.
Freyr Battery Stock Climbs. Goldman Sees an Inflation Reduction Act Winner. -- Barrons.com
3:52 pm ET August 25, 2022 (Dow Jones) Print
By Angela Palumbo
Add one more company to the list of those that stand to benefit from the Inflation Reduction Act: Freyr Battery.
Goldman Sachs analyst Philipp Konig upgraded his rating of the lithium-ion battery maker to Buy from Neutral, lifting his 12-month target for the stock price to $19 from $11. Konig cited benefits from the new law, which includes various incentives to encourage the use of green technology, a partnership to build a new factory, and the performance of Freyr's (ticker: FREY) existing plant in Norway.
Konig wrote in his research note that Freyr is planning to build a factory in the U.S. together with investment partner Koch Strategic Platforms. Production is set to start in 2025.
"Looking at the different sections of the IRA, we see strong benefits for both the supply and demand of lithium-ion batteries," Konig said, referring to the climate bill President Joe Biden signed into law earlier this month. The legislation includes a range of tax credits and rebates to encourage households to buy and use clean energy, including owning electric vehicles.
Konig noted that Freyr already has Giga Arctic, which he said is "set to be most capital efficient and sustainable gigafactory in the world." The factory is located in Norway, which Konig said is a strategic location that "offers access to the most cost competitive and sustainable energy sources globally."
Shares for Freyr soared 17% Thursday to $12.39. The stock has climbed 11% in 2022.
Other clean-energy stocks, specifically those in the solar-energy space such as First Solar (FSLR) and Array Technologies (ARRY), have also benefited from the Inflation Reduction Act.
Write to Angela Palumbo at angela.palumbo@dowjones.com
(END) Dow Jones Newswires
Picked up a few 8.60' s > Big bounce back to double digits !!!!!
STBX
LET'S GO FIGS !!!!!
Tutes, pension plans, endowment funds, and mutual funds accumulating FIGS shares.
Let's go FREY !!!!!